World News: 11:00 GMT Friday 9th November 2018. [Mesoblast Limited via Globe Newswire via SPi World News]
NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD).
The trial results will be delivered in a late-breaking clinical science session at the 2018 American Heart Association Scientific Sessions in Chicago this Sunday by independent investigators from the United States National Institutes of Health (NIH) Cardiothoracic Surgical Trials Network. The trial is being funded and sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) of the NIH, and the Canadian Institutes for Health Research.
The webcast will begin at 8.00am EST; 1.00pm BST Monday, November 12; and 12:00am AEDT Tuesday, November 13, 2018. To access the call only, dial 1 855 881 1339 (U.S.), 0800 051 8245 (toll free U.K.), 1 800 558 698 (toll free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 867444.
The live webcast can be accessed via and the archived webcast will be available on the Investor page of the Company’s website.
Globe Newswire: 11:00 GMT Friday 9th November 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.